Overexpression of EGFR in many tumor types provides a basis for the design of therapies that use EGFR as a decoy to guide effectors of the adaptive or innate immune systems to EGFR-expressing cancers and to destroy EGFR-expressing cancer cells. This evidence concerns the gene EGFR and cancer.